

***Fiscal Year 2024 Department of Defense Tick-Borne Disease Research Program (TBDRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Idea Development Award (IDA)</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942524TBDRPIDA</p>	<p>IDA:</p> <p>Independent investigators at or above the level of Assistant Professor (or equivalent).</p> <p>IDA – Career Development Option:</p> <ul style="list-style-type: none"> • Principal Investigator (PI): Investigator within 10 years of completing their terminal degree at the time of application submission deadline and working to become an independent investigator in tick-borne disease (TBD) research. • Mentor: Independent investigator at or above the level of Associate Professor (or equivalent); must be an experienced TBD researcher as demonstrated by a recent history of funding and publications in TBD research, specifically in the field of the proposed studies. • <i>Mentorship is required. The PI and Mentor may be at different organizations.</i> 	<ul style="list-style-type: none"> • IDA-specific Pathogenesis, Treatment, and Diagnosis Focus Areas only. • Supports research that could lead to impactful discoveries or significant advancements that will accelerate progress toward reducing the burden of Lyme disease and/or other TBDs and conditions and improving patient care and/or quality of life. • Research should be conceptually innovative, introduce a new concept or question, challenge existing paradigms, approach issues from a new perspective or exhibit other uniquely creative qualities. • Applications must describe the short- and long-term impact of the proposed research, as well as the public health burden of the diseases being addressed. • The Career Development Option is intended to fund early-career investigators to conduct impactful research under the mentorship of an experienced TBD researcher. Applications submitted under this option will be reviewed via separate, career development-specific evaluation criteria by a separate, dedicated peer review panel. • Inclusion of preliminary data relevant to the proposed studies is not prohibited, but in its absence, strong rationale for achieving interpretable results must be provided. • Clinical trials are not allowed; human studies/clinical research are permitted. • Pre-application submission is required; application submission is by invitation only. 	<p>IDA:</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$525,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. <p>IDA – Career Development Option:</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$350,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Preproposal): June 26, 2024 5:00 p.m. Eastern time</p> <p>Application: October 3, 2024 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Therapeutic/Diagnostic Research Award (TDRA)</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524TBDRPTDRA</p>	<p>TDRA:</p> <p>Independent investigators at or above the level of Assistant Professor (or equivalent).</p>	<ul style="list-style-type: none"> • <i>TDRA-specific Treatment and Diagnosis Focus Areas only.</i> • Supports hypothesis-driven therapeutic and diagnostic development research with demonstrated feasibility to reduce the burden of Lyme disease and/or other TBDs and conditions and improving patient care and/or quality of life. <ul style="list-style-type: none"> ◦ Treatment-focused applications should be therapeutic evaluation studies designed to advance drugs or treatments that are still in the preclinical stages of development. ◦ Diagnosis-focused applications should be diagnostic evaluation studies to advance approaches that will be readily integrated into clinical settings. • Research should have translational potential, with proposed studies expected to be empirical in nature and product-driven. • Applicants with limited TBD experience are strongly encouraged to collaborate with experienced TBD investigators. • Applicants with substantial TBD experience are strongly encouraged to partner with experts in therapeutic and diagnostic assay development and transition, particularly those from the commercial sector. • Preliminary data are required. • Clinical trials are not allowed; human studies/clinical research are permitted. • <i>Pre-application submission is required; application submission is by invitation only.</i> 	<p>TDRA:</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$830,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Preproposal): June 26, 2024 5:00 p.m. ET</p> <p>Application: October 3, 2024 11:59 p.m. ET</p>